Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Immutep Ltd

IMMP
Current price
2.08 USD -0.03 USD (-1.42%)
Last closed 0.31 AUD
Sector Healthcare
Industry Biotechnology
Exchange AU
Capitalization 358 512 722 AUD
Yield for 12 month -10.14 %
Week
Month
Year
IMMP
21.11.2021 - 28.11.2021

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The company also develops TACTI-002, which is in a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer; TACTI-003 that is in Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, which is in a Phase I clinical trial for the treatment of solid tumors, as well as INSIGHT-005 that is in Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia. Address: Australia Square, Sydney, NSW, Australia, 2000

Analytics

WallStreet Target Price

1.88 AUD

P/E ratio

Dividend Yield

Current Year

+1 136 625 AUD

Last Year

+171 259 AUD

Current Quarter

+807 223 AUD

Last Quarter

Current Year

Last Year

+171 259 AUD

Current Quarter

Last Quarter

Key Figures IMMP

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -39 778 729 AUD
Operating Margin TTM -1099.35 %
PE Ratio
Return On Assets TTM -20.75 %
PEG Ratio
Return On Equity TTM -34.61 %
Wall Street Target Price 1.88 AUD
Revenue TTM 3 524 028 AUD
Book Value 0.12 AUD
Revenue Per Share TTM 0.004 AUD
Dividend Share
Quarterly Revenue Growth YOY -30.8 %
Dividend Yield
Gross Profit TTM -32 922 486 AUD
Earnings Share -0.05 AUD
Diluted Eps TTM -0.05 AUD
Most Recent Quarter II 2023
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics IMMP

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History IMMP

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield 6.41 %
Last Split Factor 1:10
Payout Ratio
Last Split Date 05.11.2019
Dividend Date

Stock Valuation IMMP

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 994.6995
Price Sales TTM 105.1245
Enterprise Value EBITDA -5.8798
Price Book MRQ 2.6134

Financials IMMP

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators IMMP

For 52 weeks

0.22 AUD 0.42 AUD
50 Day MA 0.29 AUD
Shares Short Prior Month
200 Day MA 0.29 AUD
Short Ratio
Shares Short
Short Percent